Zydus Lifesciences Ltd, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their notable products is OLMESARTAN MEDOXOMIL USP, with a corresponding US DMF Number 24644.
Remarkably, this DMF maintains an Active status since its submission on February 16, 2011, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of April 25, 2013, and payment made on December 18, 2012, indicating their dedication to facilitating drug approvals, Categorized as Type II